...
首页> 外文期刊>Future medicinal chemistry >The development of protein tyrosine phosphatase1B inhibitors defined by binding sites in crystalline complexes
【24h】

The development of protein tyrosine phosphatase1B inhibitors defined by binding sites in crystalline complexes

机译:通过结晶配合物结合位点定义的蛋白质酪氨酸磷酸酶的抑制剂的发展

获取原文
获取原文并翻译 | 示例
           

摘要

Protein tyrosine phosphatase1B (PTP1B), a significant negative regulator in insulin and leptin signaling pathways, has emerged as a promising drug target for Type II diabetes mellitus and obesity. Numerous potent PTP1B inhibitors have been discovered within both academia and pharmaceutical industry. However, nearly all medicinal chemistry efforts have been severely hindered because a vast majority of them demonstrate poor membrane permeability and low-selectivity, especially over T-cell protein tyrosine phosphatase (TCPTP). To search the rules about the selectivity over TCPTP and membrane permeability of PTP1B inhibitors, based on the PTP1B/inhibitor crystal complexes, the development PTP1B inhibitors defined as AB, AC, ABC and ADC types have been concluded in the review.
机译:蛋白酪氨酸磷酸酶1B(PTP1B)是胰岛素和瘦素信号传导途径的显着阴性调节剂,作为II型糖尿病和肥胖症的有希望的药物靶标。 在学术界和制药行业中发现了许多有效的PTP1B抑制剂。 然而,几乎所有药物化学努力都受到严重阻碍的,因为它们的绝大部分呈现出较差的膜渗透性和低选择性,特别是在T细胞蛋白酪氨酸磷酸酶(TCPTP)上。 为了搜索关于PTP1B抑制剂的TCPTP和膜渗透性的选择性的规则,基于PTP1B /抑制剂晶体复合物,在审查中结束了定义为AB,AC,ABC和ADC类型的显影PTP1B抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号